Adma Biologics — Key Risks
Extreme Customer Concentration Creates Major Revenue Vulnerability
Just two customers — BioCare and CuraScript — accounted for about 73% of ADMA's total revenue in 2025, and 87% of its accounts receivable at year-end. Losing either of these distributors, or seeing a meaningful change in the business they send ADMA's way, could cause an immediate and severe drop in revenue.
Rare Plasma Supply Is Difficult to Source and Tightly Constrained
ADMA's flagship product ASCENIV requires plasma from donors with unusually high levels of RSV antibodies — and only less than 10% of donor samples tested actually qualify. If ADMA cannot attract enough of these rare donors or if its collection centers face regulatory or operational issues, it could run short of the raw material needed to make its most important product.
Heavy Dependence on Third Parties for Manufacturing Creates Fragility
ADMA relies on outside contractors for critical steps like fill-and-finish (the final packaging of injectable drugs). These contractors must meet strict FDA standards, and if one fails an inspection, causes a delay, or simply underperforms, ADMA's ability to ship finished product could be interrupted — with no easy backup option in place.
FDA Inspection Risk Could Halt Operations With Little Warning
Both ADMA's own facilities and its suppliers are subject to unannounced FDA inspections. A negative finding — even a moderately serious one — can trigger warning letters, production shutdowns, or product recalls. Given that ADMA already voluntarily withdrew three lots of BIVIGAM in mid-2025 (recording up to $4.0 million in revenue reductions for the first half of that year), this is not a theoretical concern.
ASCENIV's Growth Depends Entirely on Its Current FDA Approval
ADMA currently has FDA approval to market ASCENIV only for primary immune deficiency disorder (PIDD). Expanding into other conditions requires successful new clinical trials and fresh FDA approval — a process that is expensive, slow, and uncertain. Without label expansion, ADMA's revenue upside from its most important product is limited.
Profitability Is Recent and Not Yet Proven Over Time
ADMA only turned profitable in 2024 and 2025, earning $146.9 million and $197.7 million in net income respectively. Before that, it lost $28.2 million in 2023 and has an accumulated deficit of $161.7 million since its founding in 2004. Maintaining profitability requires continued revenue growth and tight execution across manufacturing and commercialization.
Medicaid Rebate Estimates Could Swing Financials Unpredictably
ADMA must estimate and set aside money for government-required Medicaid rebates, but the actual amounts owed can take years to finalize. A single reassessment in 2024 resulted in a $12.6 million favorable adjustment — meaning these estimates can move materially in either direction and distort reported earnings without reflecting any change in underlying business performance.